 Colorectal cancer, CRC, is a major health concern worldwide due to its high prevalence and mortality rate. It has been established that certain bacteria such as Fusobacterium nucleatum play a key role in the development of CRC. In order to combat this disease, researchers have developed an in-silico vaccine consisting of the B-cell and T-cell epitope regions of FAP2, a protein produced by F. Nucleatum. This vaccine has been shown to interact with human-toll-like receptor 6, TLR6, suggesting that it could potentially induce strong immune responses against CRC. Additionally, the vaccine has been successfully expressed in Escherichia coli and purified using affinity chromatography. These results suggest that the vaccine could be used as a promising therapeutic option for treating F. Nucleatum-induced CRC. This article was authored by Somrita Padma, Ritwik Patra, Parth Sartesan Gupta, and others.